Platform Trials
Discover how platform trials are transforming clinical research. Berry leads the industry with expert trial designs that leverage shared infrastructure, accelerate timelines, and reduce development costs — all while producing better patient outcomes.
One Platform, Many Possibilities
A traditional trial typically takes two years to design, create the infrastructure, and begin enrolling patients. One therapy and a control are enrolled and then the trial is over, and all the infrastructure built for the trial is obsolete and the trial addressed a single question. A platform trial is built, with a master protocol, to allow multiple therapies to be investigated in the single trial, being added continuously, all with shared infrastructure. A platform trial allows multiple arms to share a common control, share the common infrastructure of the trial, and it allows the better treatment of patients in the trial. The platform trial is a win-win for all stakeholders – smaller sample size, reduced patients on placebo, reduced costs, reduced timelines, and better inferences for regulators.
Key Advantages of Adaptive Trials
Shared Control Groups
Fewer patients required in control arms, maximizing efficiency.
Continuous Trial Design
New treatments can be added or removed as the trial progresses.
Lower Cost, Faster Results
Reuse trial infrastructure across multiple therapies, saving time and resources.
Featured Adaptive Platform Trials
Scientists from Berry are internationally renowned leaders in the creation, design, and implementation of adaptive platform trials. Platform trials designed by the team at Berry are either ongoing or being initiated in oncology, infectious diseases, pulmonary and critical care, neurology, and several rare diseases. In addition, the statisticians from Berry have extensive experience working with clinical investigators and scientific domain experts in both academic and for-profit settings. Berry has designed some of the most influential platform trials in the world, including:
